ZW800-1: The 1st Zwitterionic NIR Fluorophore for Cancer Imaging & Ureter Mapping

ZW800-1：第一个用于癌症成像的两性离子近红外荧光团

• 批准号: 10190845
• 负责人: John V Frangioni
• 金额: $ 159.57万
• 依托单位: CURADEL, LLC
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-12-08 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10190845
• 关键词: Adhesions; Adoption; Amber; Anesthesia procedures; Australia; Award; Binding; Budgets; Clinical; Contrast Media; Cyclic GMP; Development; Dose; Drug Approval; Drug Kinetics; Education; Europe; Excipients; Excision; Exhibits; Family; Fees; Freeze Drying; Funding; Goals; Grant; Healthcare Systems; Hour; Human; Human Volunteers; Image-Guided Surgery; Injections; Intravenous; Intuition; Investigational Therapies; Investments; Japan; Label; Legal patent; Light; Methods; Minor; Morbidity - disease rate; Near-infrared optical imaging; New England; Normal tissue morphology; Operative Surgical Procedures; Organ; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Phase I/II Trial; Phase III Clinical Trials; Positioning Attribute; Powder dose form; Problem Solving; Production; Renal clearance function; Risk; Savings; Services; Small Business Innovation Research Grant; Surgeon; System; Testing; Time; Toxic effect; Ureter; Urine; Validation; Vial device; analytical method; base; cGMP production; cancer imaging; cancer surgery; commercialization; cost; drug distribution; first-in-human; fluorophore; genotoxicity; imaging system; innovation; novel; phase I trial; phase II trial; polyion; programs; scale up; sterility testing; uptake

Image-guided surgery using invisible near-infrared (NIR) fluorescent light is here to stay. Multiple commercial imaging systems from Stryker, Olympus, Medtronic, and Intuitive Surgical are now available for human surgery. However, only innovative NIR fluorophores will solve major clinical problems. Curadel has invented a novel family of NIR fluorophores termed “zwitterionic,” or more precisely, geometrically-balanced, electrically-neutral, polyionic polymethine indocyanines. Zwitterionic NIR fluorophores, such as ZW800-1, exhibit ultralow non-specific binding and uptake in normal tissues and organs, as well as 100% renal clearance and elimination into urine. Within 1-10 min after a low (≤ 2.5 mg) dose intravenous (IV) injection, the ureters become highly NIR fluorescent for up to 3.6 h, thus providing surgeons with the ability to avoid them during all abdominopelvic cancer surgeries. In fact, in most cases ZW800-1 eliminates the need to surgically dissect, identify, and isolate the ureters altogether, saving over 20 min of OR time, reducing anesthesia time, and reducing the risk of complications, such as adhesions. Currently, ureter damage is quite common in cancer surgery and leads to enormous cost ($1.35B annually in the USA alone) and high patient morbidity. Because of its clinical potential, ZW800-1 was deemed a high value asset by the NCI’s Experimental Therapeutics (NExT) Program and was accepted into the first-in-human tract. Two-species toxicity, as well as genotoxicity and mutagenicity, were extraordinarily low. Curadel used a Direct-to-Phase II SBIR grant (NCI 5R44-CA-210820-02) to scale-up cGMP production, qualify impurities, and optimize aseptic fill-finish, while collaborators in Europe performed a Phase 1 trial on human volunteers and a Phase 2 trial on patients undergoing abdominopelvic surgery for cancer resection. The results of the Phase 1 and 2 trials presented herein are exceptional and validate our hypothesis that ZW800-1 is an ideal contrast agent for ureter mapping. A single low dose permitted ureter mapping for hours on FLARE®, Olympus®, and Da Vinci® NIR fluorescence imaging systems, and could be repeated if needed for longer cases. ZW800-1 is now poised to complete the remaining steps of market approval where we anticipate widespread adoption in abdominopelvic cancer surgery. Innovative aspects of our application include a cGMP synthesis and aseptic fill-finish strategy that does not require excipients or other additives yet results in a final drug product with > 5 years of stability, and a commercialization plan that requires only ≈ $8M to get to NDA submission yet results in a commercial product with >93% gross margin and a $100M+ annual market. Our competitive position is also unusually strong because of issued patent claims for ZW800-1 in USA, Europe, Japan, and Australia, and unique pharmacokinetics that no other competing NIR fluorophore can match. Our long-term goal is to solve the problem of ureter mapping during cancer surgery once and for all.

使用不可见的近红外（NIR）荧光灯的图像引导手术将继续存在。多个